GenEdit is focused on overcoming the major challenge to genetic medicines:  Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.  

The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.

We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.


Qiming Venture Partners

SkyDeck Berkeley

Sequoia Capital

Bow Capital

SK Holdings

DCVC Bio

ACVC

Huons

Pathway Partners

Terra VC

Dong-A ST

K2 Investment Partners

KIMCO

Korea Development Bank

loftyrock investment

Mirae Asset Venture Investment

Company K Partners

IMM Investment

Time Folio Asset Management

Timepolio Asset Management

Dayli Partners

Korea Investment Partners

DAOL Investment & Securities

KTB Network

GenEdit

We held an exciting GenEdit Day, which is a recurring event to gather and review our company progress. This year we celebrated our partnership with Genentech, reviewed our latest data and finished the day with a fun team-building activity.


We're excited to announce a collaboration with Genentech to discover and develop novel nanoparticles with our #Nanogalaxy platform to deliver Genentech’s nucleic acid-based medicines for treatment of #autoimmunedisease. 

Read the release here: https://lnkd.in/gvh8J4T6

#geneticmedicines

We are pleased to announce that the GenEdit team is a Phase I winner of the National Institutes of Health TARGETED Challenge for programmable delivery systems for gene editing. The award is a recognition of the potential of our NanoGalaxy® platform for a broad range of genetic medicines for multiple therapy areas.


An alternative gene editing technology to CRISPR Cas9, focusing on recombineering.

Retron Library Recombineering (RLR) Platform

A competitor to CRISPR Cas9, specializing in CLOVER nucleases for gene editing.

Cas-CLOVER Nucleases

A gene editing technology company focused on zinc finger nucleases for precise genome modifications.

Zinc Finger Nucleases

A company utilizing CRISPR genome editing technology for the discovery and development of novel therapeutic candidates.

Synthego

Known for its innovative base editing technology, enabling precise modifications of DNA.

Beam Therapeutics

A gene therapy company with the potential to transform the medical industry.

Bluebird Bio

A gene therapy company with innovative approaches to medical treatments.

4D Molecular Therapeutics

A company focused on gene therapy with potential transformative impact on the medical industry.

Genprex, Inc.

A gene therapy company with innovative medical applications.

Poseida Therapeutics

A leading company in the global genome editing market, offering a wide range of genome editing solutions.

Thermo Fisher Scientific

A prominent player in the global genome editing market, known for its contributions to the field.

Merck KGaA

A key player in the global genome editing market, offering various genome editing solutions.

GenScript

A company specializing in genome editing technologies for therapeutic applications.

Sangamo Therapeutics

GeneEdit is a biotechnology company focused on developing next-generation gene editing technologies for therapeutic applications. Their proprietary platform aims to enable safer and more precise genome editing for the treatment of various genetic diseases.

GeneEdit

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 11, 2024 8:41 AM	3c3a2403
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 11, 2024 8:57 AM	89e1d983
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 11, 2024 8:41 AM	033164fd
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 11, 2024 8:41 AM	7d9c911f
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:GENEDIT

GeneEdit